VANDERSON GERALDO ROCHA
Projetos de Pesquisa
Unidades Organizacionais
Departamento de Clínica Médica, Faculdade de Medicina - Docente
Instituto Central, Hospital das Clínicas, Faculdade de Medicina
LIM/31 - Laboratório de Genética e Hematologia Molecular, Hospital das Clínicas, Faculdade de Medicina - Líder
Instituto Central, Hospital das Clínicas, Faculdade de Medicina
LIM/31 - Laboratório de Genética e Hematologia Molecular, Hospital das Clínicas, Faculdade de Medicina - Líder
50 resultados
Resultados de Busca
Agora exibindo 1 - 10 de 50
- The impact of low dose busulfan on gonodal function after allogeneic hematopoietic stem cell transplantation for aplastic anemia(2020) KERBAUY, Mariana Nassif; MARIANO, Livia; SEBER, Adriana; ROCHA, Vanderson
- Immunological signatures unveiled by integrative systems vaccinology characterization of dengue vaccination trials and natural infection(2024) PLACA, Desiree Rodrigues; FONSECA, Dennyson Leandro M.; MARQUES, Alexandre H. C.; POUR, Shahab Zaki; USUDA, Julia Nakanishi; BAIOCCHI, Gabriela Crispim; PRADO, Caroline Aliane de Souza; SALGADO, Ranieri Coelho; FILGUEIRAS, Igor Salerno; FREIRE, Paula Paccielli; ROCHA, Vanderson; CAMARA, Niels Olsen Saraiva; CATAR, Rusan; MOLL, Guido; JURISICA, Igor; CALICH, Vera Lucia Garcia; GIIL, Lasse M.; RIVINO, Laura; OCHS, Hans D.; CABRAL-MIRANDA, Gustavo; SCHIMKE, Lena F.; CABRAL-MARQUES, OtavioIntroduction Dengue virus infection is a global health problem lacking specific therapy, requiring an improved understanding of DENV immunity and vaccine responses. Considering the recent emerging of new dengue vaccines, here we performed an integrative systems vaccinology characterization of molecular signatures triggered by the natural DENV infection (NDI) and attenuated dengue virus infection models (DVTs).Methods and results We analyzed 955 samples of transcriptomic datasets of patients with NDI and attenuated dengue virus infection trials (DVT1, DVT2, and DVT3) using a systems vaccinology approach. Differential expression analysis identified 237 common differentially expressed genes (DEGs) between DVTs and NDI. Among them, 28 and 60 DEGs were up or downregulated by dengue vaccination during DVT2 and DVT3, respectively, with 20 DEGs intersecting across all three DVTs. Enriched biological processes of these genes included type I/II interferon signaling, cytokine regulation, apoptosis, and T-cell differentiation. Principal component analysis based on 20 common DEGs (overlapping between DVTs and our NDI validation dataset) distinguished dengue patients by disease severity, particularly in the late acute phase. Machine learning analysis ranked the ten most critical predictors of disease severity in NDI, crucial for the anti-viral immune response.Conclusion This work provides insights into the NDI and vaccine-induced overlapping immune response and suggests molecular markers (e.g., IFIT5, ISG15, and HERC5) for anti-dengue-specific therapies and effective vaccination development.
conferenceObject Use of Extracorporeal Photopheresis for the Treatment of Steroid Refractory Acute Graft-Versus-Host Disease in Pediatric Patients: Experience at a Private Institution in Brazil(2020) NEVES, Raquel; GOMES, Alessandra; MAFRA, Ana Beatriz; FATOBENE, Giancarlo; ROCHA, Vanderson- Multicenter Long-Term Follow-Up of Allogeneic Hematopoietic Cell Transplantation with Omidubicel: A Pooled Analysis of Five Prospective Clinical Trials(2023) LIN, Chenyu; SCHWARZBACH, Aurelie; SANZ, Jaime; MONTESINOS, Pau; STIFF, Patrick; PARIKHA, Suhag; BRUNSTEIN, Claudio; CUTLER, Corey; LINDEMANS, Caroline A.; HANNA, Rabi; KOH, Liang Piu; JAGASIA, Madan H.; VALCARCEL, David; MAZIARZ, Richard T.; KEATING, Amy K.; HWANG, William Y. K.; REZVANI, Andrew R.; KARRAS, Nicole A.; FERNANDES, Juliana F.; ROCHA, Vanderson; BADELL, Isabel; RAM, Ron; SCHILLER, Gary J.; VOLODIN, Leonid; WALTERS, Mark C.; HAMERSCHLAK, Nelson; CILLONI, Daniela; FRANKFURT, Olga; MCGUIRK, Joseph P.; KURTZBERG, Joanne; SANZ, Guillermo; SIMANTOV, Ronit; HORWITZ, Mitchell E.Omidubicel is an umbilical cord blood (UCB)-derived ex vivo-expanded cellular therapy product that has dem-onstrated faster engraftment and fewer infections compared with unmanipulated UCB in allogeneic hematopoietic cell transplantation. Although the early benefits of omidubicel have been established, long-term outcomes remain unknown. We report on a planned pooled analysis of 5 multicenter clinical trials including 105 patients with hematologic malignancies or sickle cell hemoglobinopathy who underwent omidubicel transplantation at 26 academic transplantation centers worldwide. With a median follow-up of 22 months (range, .3 to 122 months), the 3-year estimated overall survival and disease-free survival were 62.7% and 56.4%, respectively. With up to 10 years of follow-up, omidubicel showed durable trilineage hematopoiesis. Serial quantitative assessments of CD3(+), CD4(+), CD8(+), CD19(+), CD116(+)CD56(+), and CD123(+) immune subsets revealed median counts remaining within normal ranges through up to 8 years of follow-up. Secondary graft failure occurred in 5 patients (5%) in the first year, with no late cases reported. One case of donor-derived myeloid neoplasm was reported at 40 months post-transplantation. This was also observed in a control arm patient who received only unmanipulated UCB. Overall, omidubicel demonstrated stable trilineage hematopoiesis, immune competence, and graft durability in extended follow-up. (c) 2023 The American Society for Transplantation and Cellular Therapy.
conferenceObject Donor-Recipient HLA Matching for Unrelated Donor Hematopoietic Stem Cell Transplantation Outcomes: A Study from the Cellular Therapy and Immunobiology Working Party (CTIWP) of the EBMT(2020) RUGGERI, Annalisa; MUELLER, Carlheninz; MAUFF, Katya; WREEDE, Lisbeth de; WIETEN, Lotte; VAGO, Luca; HOOGENBOOM, Jorinde; SOCIE, Gerard; NIITTYVUOPIO, Riitta; YAKOUBAGHA, Ibrahim; CRAWLEY, Charles; THOLOULI, Eleni; BULABOIS, Claude Eric; CHOI, Goda; FORCADE, Edouard; HUYNH, Anne; LENHOFF, Stig; GANDEMER, Virginie; CICERI, Fabio; KROEGER, Nicolaus; MAILLARD, Natacha; ITALA-REMES, Maija; ROCHA, Vanderson; BONINI, Chiara; CHABANNON, Christian; FLEISCHHAUER, KatharinaconferenceObject Impact of Covid-19 Pandemic on Release of French Cord Blood Units. on Behalf The Agency of Biomedicine, Eurocord And The SFGM-TC(2021) AYOUBI, Hanadi Rafii-El; IONESCU, Irina; RUGGERI, Annalisa; GARNIER, Federico; BALLOT, Caroline; BENSOUSSAN, Daniele; CHABANNON, Christian; DAZEY, Bernard; VOS, John De; GAUTIER, Eric; GIRAUD, Christine; LARGHERO, Jerome; CRAS, Audrey; MIALOU, Valerie; PERSOONS, Virginie; POUTHIER, Fabienne; THIBERT, Jean-Baptiste; DALLE, Jean-Hugues; MICHEL, Gerard; VOLT, Fernanda; KENZEY, Chantal; ROCHA, Vanderson; BAY, Jacques-Olivier; RUBIO, Marie-Therese; FAUCHER, Catherine; MARRY, Evelyne; GLUCKMAN, Eliane- Outcomes of Unmanipulated Haploidentical Transplantation Using Post-Transplant Cyclophosphamide (PT-Cy) in Pediatric Patients With Acute Lymphoblastic Leukemia(2021) RUGGERI, Annalisa; GALIMARD, Jacques-Emmanuel; PAINA, Olesya; FAGIOLI, Franca; TBAKHI, Abdelghani; YESILIPEK, Akif; NAVARRO, Jose Maria Fernandez; FARACI, Maura; HAMLADJI, Rose-Marie; SKOROBOGATOVA, Elena; AL-SERAIHY, Amal; SUNDIN, Mikael; HERRERA, Concepcion; RIFON, Jose; DALISSIER, Arnaud; LOCATELLI, Franco; ROCHA, Vanderson; CORBACIOGLU, SelimHLA-haploidentical transplantation (haplo-HCT) using post-transplantation-cyclophosphamide (PT-Cy) is a feasible procedure in children with malignancies. However, large studies on Haplo-HCT with PT-Cy for childhood acute lymphoblastic leukemia (ALL) are lacking. We analyzed haplo-HCT outcomes in 180 children with ALL. Median age was 9 years, and median follow-up was 2.7 years. Disease status was CR1 for 24%, CR2 for 45%, CR+3 for 12%, and active disease for 19%. All patients received PT-Cy day +3 and +4. Bone marrow (BM) was the stem cell source in 115 patients (64%). Cumulative incidence of 42-day engraftment was 88.9%. Cumulative incidence of day-100 acute graft-versus-host disease (GVHD) grade II-IV was 28%, and 2-year chronic GVHD was 21.9%. At 2 years, cumulative incidence of nonrelapse mortality (NRM) was 19.6%. Cumulative incidence was 41.9% for relapse and 25% for patients in CR1. Estimated 2-year leukemia free survival was 65%, 44%, and 18.8% for patients transplanted in CR1, CR2, CR3+ and 3% at 1 year for active disease. In multivariable analysis for patients in CR1 and CR2, disease status (CR2 [hazard ratio {HR} = 2.19; P = .04]), age at HCT older than 13 (HR = 2.07; P = .03) and use of peripheral blood stem cell (PBSC) (HR = 1.98; P = .04) were independent factors associated with decreased overall survival. Use of PBSC was also associated with higher NRM (HR = 3.13; P = .04). Haplo-HCT with PT-Cy is an option for children with ALL, namely those transplanted in CR1 and CR2. Age and disease status remain the most important factors for outcomes. BM cells as a graft source is associated with improved survival.
conferenceObject Influence of The SARS-COV-2 Pandemic on Bone Marrow Transplantation Centers And The Protocols Adopted In Brazil Between May And June 2020(2021) DUARTE, Fernando; SOUSA, Talyta Ellen Jesus Santos; HALLACK NETO, Abrahao Elias; SEBER, Adriana; VIGORITO, Afonso Celso; LOURENCO, Andre Luis Gervatoski; MELO, Andresa Lima; DUARTE, Beatrice Araujo; ARAUJO, Beatriz Stela Gomes Souza Pitombeira; BONFIM, Carmem; ARRAIS, Celso; BARIAN, Cesar; KUWAHARA, Cilmara; LERNER, Decio; PATON, Eduardo Jose de Alencar; VIEIRA, Garles Miller Matias; BARROS, George Mauricio Navarro; LOTH, Gisele; TEIXEIRA, Gustavo Machado; SCHMIDT FILHO, Jayr; FELICIANO, Joao Victor Piccolo; FOGLIATTO, Laura Maria; GRILO, Leandro Celso; MARTINS, Leticia Navarro Gordan Ferreira; DAUDT, Liane Esteves; BOUZAS, Luis Fernando da Silva; MONCAO, Marcio Soares; SALVINO, Marco Aurelio; MOREIRA, Maria Claudia; MACEDO, Maria Cristina M. Almeida; COUTINHO, Marina Assirati; HAMERSCHLAK, Nelson; CHIATTONE, Ricardo; SILVA, Roberto Luiz da; SOARES, Rodolfo; SCHAFFEL, Rony; PASSOS, Roselene Mesquita Augusto; VIANA, Thaisa Marjore Menezes; MONTEIRO, Tatiana Dias Marconi; FUNKE, Vaneuza Araujo Moreira; COLTURATO, Vergilio Antonio Rensi; ZECCHIN, Victor Gottardello; AZEVEDO, Wellington Morais de; NOVIS, Yana Augusta S.; SILVA, Leandro de Padua; ZANETTE, Antonella; CUNHA, Renato Luiz Guerino; FAGUNDES, Evandro Maranhao; ATALLA, Angelo; ROCHA, Vanderson- Outcomes after Haploidentical Hematopoietic Cell Transplantation with Post-Transplantation Cyclophosphamide: A Systematic Review and Meta-Analysis Comparing Myeloablative with Reduced-Intensity Conditioning Regimens and Bone Marrow with Peripheral Blood Stem Cell Grafts(2021) ARCURI, Leonardo Javier; HAMERSCHLAK, Nelson; ROCHA, Vanderson; BONFIM, Carmem; KERBAUY, Mariana NassifHaploidentical hematopoietic cell transplantation (haplo-HCT) with post-transplantation cyclophosphamide (PTCy) may be the sole available curative option for several hematologic malignancies. However, the best choice of conditioning regimen and graft source has not been established. This study was conducted to compare myeloablative conditioning (MAC) regimens with reduced-intensity conditioning (RIC) regimens and peripheral blood stem cell (PBSC) grafts with bone marrow (BM) grafts in the haplo-HCT setting with PTCy. We performed a systematic review andmeta-analysis of studies comparing MAC with RIC and PBSC with BM in the haplo-HCT. The search was conducted in PubMed and TRIALS on February 2, 2021, without a date limit. We excluded studies with >30% non-PTCy graft-versus-host disease (GVHD) prophylaxis and >30% nonmalignant diseases. We screened 570 abstracts from PubMed and TRIALS and selected 20 for full-text review and 17 for inclusion in the qualitative and quantitative analyses. For PBSC versus BM grafts, we found no difference in overall survival (OS; hazard ratio [HR], 1.05; P = .61; nPBSC = 1983; nBM = 2124), progression-free survival (PFS; HR, 0.95; P = .52; nPBSC = 2663, nBM = 2769), graft-versus-host disease (GVHD)-free relapse-free survival (GRFS; HR, 1.16; P = .07; nPBSC = 1454; pBM = 1647), or nonrelapse mortality (HR, 1.14; P = .13; nPBSC = 1664; nBM = 1862). Relapse was lower with the use of PBSC grafts (HR, 0.84; P = .001; nPBSC = 2663; nBM = 2769). The rates of acute GVHD (aGVHD) and chronic GVHD (cGVHD) were higher with PBSC grafts (aGVHD grade II-IV: HR, 1.67; P < .001; nPBSC = 2663; nBM = 2802; aGVHD grade III-IV: HR, 1.82; P < .001; nPBSC = 1826; nBM = 2000; cGVHD: HR, 1.46; P = .002; nPBSC = 2686; nBM = 2815). Engraftment was higher with PBSC grafts (HR, 1.27; P < .001; nPBSC = 1461; nBM = 1717). Comparing MAC and RIC, the use of MAC was associated with less relapse (HR, 0.70; P < .001; nMAC = 1929; nRIC = 2662), higher nonrelapse mortality (HR, 1.24; P = .002; nMAC = 2016; nRIC = 2790), but better PFS (HR, 0.86; P = .002; nMAC = 1929; nRIC = 2662). There were no differences between the 2 conditioning regimens in OS (HR,.95; P = .32; nMAC = 2123; nRIC = 3155), GRFS (HR, 0.97; P = .67; nMAC = 1182; nRIC = 1330), grade II-IV aGVHD (HR, 1.01; P = .81; nMAC = 2099; nRIC = 3090), or cGVHD (HR, 1.05; P = .44; nMAC=1929; nRIC = 2662). This analysis shows that the use of BM grafts is associated with comparable outcomes as seen with PBSC grafts despite a lower incidence of GVHD and a higher relapse rate. The use of MAC regimens is associated with improved PFS. These results suggest that for fit patients, MAC remains the optimal conditioning regimen in terms of mortality, and that the use of PBSC grafts may further decrease relapse risk and hasten engraftment, provided that further strategies can be incorporated to decrease GVHD. Prospective comparisons are awaited.
- HLA-Matched Unrelated Donors for Patients with Sickle Cell Disease: Results of International Donor Searches(2020) TOZATTO-MAIO, Karina; TORRES, Margareth Afonso; DEGAIDE, Neifi Hassan Saloum; CARDOSO, Juliana Fernandes; VOLT, Fernanda; PINTO, Ana Cristina Silva; OLIVEIRA, Danielli; ELAYOUBI, Hanadi; KASHIMA, Simone; LOISEAU, Pascale; VEELKEN, Hendrik; FERSTER, Alina; CAPPELLI, Barbara; RODRIGUES, Evandra Strazza; SCIGLIUOLO, Graziana Maria; KENZEY, Chantal; RUGGERI, Annalisa; ROCHA, Vanderson; SIMOES, Belinda Pinto; TAMOUZA, Ryad; GLUCKMAN, ElianeSickle cell disease (SCD) is the most common inherited hemoglobinopathy. Hematopoietic stem cell transplantation (HCT) is the sole curative therapy for SCD, but few patients will have a matched sibling donor. Patients with SCD are mostly of African origin and thus are less likely to find a matched unrelated donor in international registries. Using HaploStats, we estimated HLA haplotypes for 185 patients with SCD (116 from a Brazilian center and 69 from European Society for Blood and Marrow Transplantation [EBMT] centers) and classified the ethnic origin of haplotypes. Then we assessed the probability of finding an HLA-matched unrelated adult donor (MUD), considering loci A, B, and DRB1 (6/6), in international registries. Most haplotypes were African, but Brazilians showed a greater ethnic admixture than EBMT patients. Nevertheless, the chance of finding at least one 6/6 potential allelic donor was 47% for both groups. Most potential allelic donors were from the US National Marrow Donor Program registry and from the Brazilian REDOME donor registry. Although the probability of finding a donor is higher than previously reported, strategies are needed to improve ethnic diversity in registries. Moreover, predicting the likelihood of having an MUD might influence SCD management. (C) 2020 American Society for Transplantation and Cellular Therapy.